Tiziana Life Sciences Plc
140 articles with Tiziana Life Sciences Plc
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock repurchase program for up to $5 million of the Company’s common shares at any time.
Tiziana Life Sciences today announced that Dr. Thomas Adams passed away on January 9, 2022.
Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences is pleased to announce that the U.S. Food and Drug Administration allowed enrollment of a second patient in the ongoing clinical treatment of secondary progressive multiple sclerosis with intranasally administered foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women’s Hospital, Harvard University, Boston, MA.
Tiziana Life Sciences, a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced that senior management will present at the Biotech Showcase Conference and be available for one-on-one meetings throughout the conference.
Tiziana Life Sciences plc announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 100,000 ordinary shares of 3p each in the market at a price of 52p per share.
Tiziana Life Sciences plc, a biotechnology company a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announces its interim results for the six months ended 30 June 2021.
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Tiziana Life Sciences plc will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company’s novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment.
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Precision BioSciences, Inc. and Tiziana Life Sciences plc announced an exclusive license agreement to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody, as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy.
Tiziana Life Sciences plc today announces that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“ New Tiziana ”), a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group.
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil
Tiziana Life Sciences plc announces publication of a scientific article in the peer-reviewed journal Frontiers in Immunology titled "Nasal Administration of Anti-CD3 Monoclonal Antibody Reduces Lung Inﬂammation and Blood Inﬂammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study".
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited.
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today
Tiziana Life Sciences plc announces an interview with the Chairman of its’ Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Tiziana Life Sciences plc announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization, to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 and pulmonary inflammation.
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin Schutz, PharmD, as Vice-President of Regulatory Affairs.
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
Tiziana Life Sciences plc announces that it has submitted a grant to the United Kingdom COVID Therapeutics Advisory Panel to support further clinical development of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, as an innovative ‘Take Home’ approach for treatment of non-hospitalized patients with COVID-19.
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, provided an update on further analysis of lymphocyte subsets from blood samples from a Phase 1 study with nasally administered Foralumab in healthy volunteers.
Tiziana Life Sciences Announces Initiation of Clinical Trial in a SPMS Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical responses.
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announced an interview with CEO and CSO Dr. Kunwar Shailubhai will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, May 8 at 7 p.m. local time.
Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan K.K, Pharma Team, for a strategic business development plan to Identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma patients.
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announced its CEO and CSO Dr. Kunwar Shailubhai and the chair of its Scientific Advisory Committee, Dr Howard Weiner, will participate in a fireside chat via a video link on Wednesday, 28 April 2021 at 10:30 a.m. EDT to provide updates on the Company.